Metaiodobenzylguanidine (MIBG), a noradrenaline analogue, labelled with radioactive iodine I-123 is used for assessing pre-synaptic activity of the myocardial adrenergic system. The paper describes the mechanism of myocardial I-123-MIBG uptake and the relevant examination methods. It also refers to the necessity of standardising acquisition methods and assessment criteria in order to improve comparability of results, especially numerical results, originating from various countries and centres.
Introduction
The autonomic nervous system consists of the adrenergic (sympathetic) system with stimulating action -and noradrenaline as the main transmitter, and the cholinergic (parasympathetic) system with inhibiting action -and acetylcholine as the main transmitter. The imaging of the cardiac cholinergic system is very limited due to the low density of parasympathetic nerves in the ventricular muscles and the lack of appropriate analogues of acetylcholine, which undergoes rapid decomposition in the presynaptic nerve terminals, suitable for radioisotope examinations.
However, the adrenergic fibres are abundant in the heart -they run in the epicardium along the coronary arteries and penetrate the myocardium similarly as the smaller coronary vessels; they are present in the ventricles (in particular at the base thereof) and to a significant extent are more concentrated in the atria.
Metaiodobenzylguanidine (MIBG) is a chemical analogue of noradrenaline -its uptake and storage mechanisms in the adrenergic nerve terminals are similar to those of noradrenaline, while it hardly undergoes metabolism and remains unchanged for a longer period of time in the nerve terminals -therefore, when labelled with radioactive iodine, it is considered a pharmaceutical suitable for the assessment of the presynaptic portion of the cardiac adrenergic innervation [1] [2] [3] [4] [5] [6] .
As the radiation energy (159 keV) of radioactive iodine I-123 is comparable to that of technetium Tc-99m (thus it is possible to use low-energy collimators and acquire relatively high-resolution scintigraphic images) and it has comparatively short half-life (13.3 h), it currently seems to be the best one of the available iodine radioisotopes for MIBG labelling.
The I-123-MIBG radiotracer, used for assessing the presynaptic part of the adrenergic system, is the most extensively researched and practically the only radiotracer available in the classical scintigraphy of the cardiac autonomic nervous system. This radiotracer was first used for the assessment of a human heart by Kline et al. in 1981 [1] .
Other imaging agents include noradrenaline analogues labelled with positron radiotracers for PET scintigraphy (hydro xyephedrine, epinephrine and phenylephrine labelled with C-11 [7] and a completely new LMI1195 radiotracer for labelling with F-18 which has a longer half-life [8] ).
The research is also underway into the labelling of post-synaptic receptors which transmit signals from the adrenergic system to Description of MIBG uptake, examination methods and interpretation of results
Mechanism of the myocardial MIBG uptake
Following intravenous administration, MIBG diffuses from the vascular to the intracellular space, and from there it is actively transported, similarly as noradrenaline, to the adrenergic terminals or a small fraction of MIBG diffuses (to neurons, muscle cells, the vascular space).
The first mechanism (so-called uptake-1, energy-dependent) is the prevailing mechanism. From the synaptic cleft, MIBG undergoes active uptake at the nerve terminal which is facilitated by the specific noradrenaline monoamine transporter (NET) protein and most of the radiotracer, by means of another active transport process facilitated by the specific vesicular monoamine transporter (VMAT) protein, is stored in noradrenaline-storing vesicles in the neuron's terminal. Uptake-1 becomes saturated. Nerve stimulation induces the secretion of noradrenaline and MIBG: vesicles combine with the neuron's membrane and secrete their content to the synaptic space by exocytosis. Metaiodobenzylguanidine is re-transported to the nerve terminal by the uptake-1 mechanism or diffuses (into the vascular space and conceivably to neurons, and also to myocytes in animals). Unlike the noradrenaline fraction which is not stored in the vesicles, but metabolised in the cytosol of the nerve terminal [by monoamine oxidase (MAO)], MIBG is not catabolised -therefore the extravesicular concentration of MIBG is larger than that of noradrenaline. Metaiodobenzylguanidine can diffuse from the cytosol of the nerve terminal into the intracellular space.
The mechanism eliminating noradrenaline into the extraneural tissue (sometimes called uptake-2) is probably based on passive diffusion. Uptake-2 has no saturation point. It was shown using animal models that the extraneural uptake-2 of MIBG can reach a significant level. However, it is not the same in humans -no MIBG uptake is observed in the transplanted (and initially fully de-innervated) heart until at least 4 months after the transplantation. In contrast to noradrenaline, MIBG in the cardiomyocyte cytosol is not catabolised by catechol-O-methyltransferase (COMT).
The compound exhibits low affinity to post-synaptic adrenergic receptors, and for that reason -as opposed to noradrenaline -has a highly insignificant pharmacological effect. It was demonstrated that the level of myocardial MIBG uptake is correlated with the myocardial noradrenaline level [13] and it is explicitly dependent on the presence of non-damaged sympathetic nerve fibres [14] [15] [16] [17] .
MIBG pharmacokinetics and pharmacodynamics
The dynamics of myocardial MIBG accumulation can be described as follows:
-after intravenous administration, myocardial MIBG uptake follows immediately and achieves a stable level after 2-3 minutes [60] , after 60 minutes it reaches about 1% of the administered dosage [1] ;
-intravesicular myocardial accumulation of I-123-MIBG is relatively constant starting from the 5 th minute after administration, while extravesicular myocardial accumulation decreases to a significant extent between the 5 th minute and 6 th hour after the administration; the intravesicular percentage of the total myocardial accumulation achieves a constant (and maximal) value equal to 50% within 4 hours after the administration;
hence it is considered that images acquired about 4 hours after the injection of the tracer would best reflect the neuronal MIBG uptake in the heart [19] .
MIBG pharmacokinetics and pharmacodynamics in the human body is as follows:
-I-123-MIBG blood level decreases quite rapidly: about 10%
of the injected dosage remains in blood after 5 minutes from the administration, about 5% after 15 minutes, and about 2%
-the highest MIBG fraction is accumulated in the liver (about 0.33 of the administered dosage), the greatest uptake is observed in the lungs (about 0.03), the heart (0.008), the spleen (about 0.006) and in the salivary glands (about 0.004);
-tracer uptake in the liver is always greater compared to the heart: the ratio of the myocardial-to-hepatic uptake is about 
MIBG examinations of the myocardial adrenergic system
Acquisition parameters recommended for cardiac I-123-MIBG studies are shown in Table 1 .
Normal-weight adult patients are administered a dosage of 111-370 MBq (3-10 mCi) of the radiopharmaceutical [25] . MIBG should be administered intravenously very slowly (for at least 1-2 minutes according to [25] , and for at least 5 minutes according to [24] ). [29] . Furthermore the H/M ratio is correlated with the myocardial noradrenaline level (r = 0.63) [13] . Thus, the H/M ratio is a measure of the global myocardial MIBG uptake and can be used as a practical rate of uptake [29] [30] [31] .
The washout rate (WR) of MIBG from the heart is most often expressed as a percentage difference between the average number of counts within the heart after 15 minutes and 4 hours and the average number of counts within the heart after 15 minutes.
However, there is a wide variety of calculation methods -with or without standardisation of H-to-M counts, with or without background correction by subtracting M counts from H counts, with or without correction for radioisotope decay in time [25, 32, 33] .
The washout rate of MIBG from the heart indicates the excitation level of the adrenergic system (greater activity of the myocardial adrenergic system is related to the high WR value and low MIBG uptake in late images). Nonetheless, there are doubts about the interpretation of the washout rate -most probably it represents several mechanisms (at least vesicular exocytosis and extravesicular diffusion in the nerve terminals). Greater WR values were described in a number of cardiological diseases -but the mechanisms responsible for the phenomenon have not been fully explained.
Most often the H/M ratio, in particular after 4 hours from the MIBG administration, is considered to be the most important factor in the global assessment of the myocardial adrenergic system -also on account of the larger number of studies in which this parameter was tested. However, it has not been unambiguously determined whether any single parameter -H/M or WR -or their combination should be taken into consideration in the prognostic process.
SPECT-based assessment of the regional myocardial MIBG uptake
The papers known from the literature on the SPECT-based examination of "normal" myocardial I-123-MIBG uptake, performed within several hours after the administration of radiotracer, were related to the relative assessment of the radiotracer distribution in specific regions of the left-ventricular muscle and the determination of the correlation between the distribution and the patient's sex and/or age [34] [35] [36] [37] [38] . Normal I-123-MIBG uptake in the left-ventricular muscle is non-uniform and depends on the patient's age and probably sex. It also seems that the normal relative uptake in specific regions is comparable to the relative uptake of perfusion tracers in the muscle: the greatest number of counts is observed above the anterolateral wall, the lowest number above the lower wall (especially in men). Reduced number of counts can be present in the apex. The nerves of the cardiac adrenergic system are more sensitive to ischaemia than cardiomyocytes. Therefore, the defects observed in MIBG rest images are bigger (more extensive and more intense) than the rest perfusion defects and more often are similar to stress-induced ischaemic perfusion defects ( Figure 2 ).
It should be noted that if the primary objective of the MIBG uptake assessment is not to diagnose the myocardial adrenergic innervation in a given population (compared to normal results), but the evaluation of any expected regional changes in the innervation in relation to the initial condition of a given patient or of any differences in the regional innervation between well-defined groups of patients, then it is not critically necessary to have maps of normal uptake levels.
The quality of I-123-MIBG SPECT can be much lower than the quality of SPECT-based myocardial perfusion with technetium tracers. As many as 16% of the I-123-MIBG SPECT examinations carried out by our team [39] were non-diagnostic studies due to the very low uptake level within the myocardium and/or very high radioactivity in non-myocardial structures (liver, bowels, lungs), the images of which were not separated from myocardial images. Also
Gill et al. [34] reported that the artefacts on the inferior left ventricu- Review lar wall -due to the very high MIBG uptake in the liver or spleen in SPECT images registered within 3 hours after the administration of the tracer -were so frequent that the authors decided to discontinue the assessment of radiotracer distribution in this wall.
Necessity of standardisation of MIBG examinations
During their retrospective assessment of the studies relating to the myocardial adrenergic system, Agostini, Verberne and Jacobson determined large differences in the acquisition methods applied in Europe, which could affect the resulting parameters of the global MIBG uptake [27] . Their efforts to standardise the technical aspects of the procedure (and thus to increase the prospect that it is accepted as a clinical tool for patients with heart failure) [32, 33] resulted in a proposal for standardisation of I-123-MIBG imaging of the myocardial adrenergic system, announced by the Cardiovascular Committee of the European Association of Nuclear Medicine and the European Council of Nuclear Cardiology [25] . It should contribute to reducing differences between results, including numerical results, originating from various countries and centres [40] .
Clinical applications of I-123-MIBG myocardial examinations
Although first introduced as a cardiac diagnostic procedure in the early 1980s, I-123-MIBG myocardial scintigraphic methods continue to be mostly applied in scientific research (Table 2) .
Their advantage over the existing diagnostic methods has not been sufficiently documented (lack of multi-centre randomised studies with large groups of patients), even though there are numerous reports of the diagnostic and/or prognostic importance of this examination, especially in the case of heart failure. The testing results of MIBG-based examinations have been described for a variety of other heart diseases, including: primary arrhythmias [41] [42] [43] , myocardial ischaemia with infarction [14] [15] [16] [17] or without [44] [45] [46] [47] [48] , in the assessment of the development of the innervation system after heart transplant [11, 12, 49] , in the assessment of cardiotoxicity of anticancer chemotherapy [50] [51] [52] . There are also numerous reports showing that the I-123-MIBG imaging enables effective monitoring of the effects of conventional pharmacological therapies; images of MIBG uptake are improved after therapy with beta-blockers and often associated with reduced volume of the ventricles, better LVEF and reduced symptoms of heart failure; carvedilol has been most extensively researched in this respect (the recent randomised multi-centre double-blind placebo-controlled study was the French study described by showed that a damage of the myocardial adrenergic system can be responsible for the significant clinical improvement generally observed at an early stage after TMLR, however, in the light of reinnervation, it is not responsible for the improvement covering a period of several years [64] [65] [66] [67] .
Most recently MIBG imaging was applied for the assessment of cardiac involvement and prediction of cardiac events in patients with Churg-Strauss syndrome (a rare variety of systemic vasculitis, often involving myocardial vessels) [68] .
Below are discussed results of the studies relating to some selected clinical situations which have been described in a number of publications and new original works published over the past 2 years, which shows the continuous/increasing interest in I-123-MIBG myocardial examinations.
I-123-MIBG examinations in heart failure
The clinical applications of I-123-MIBG in cardiology have been most extensively examined in patients with heart failure.
Heart failure (HF) is a condition with clinical symptoms of impaired heart performance -patients experience shortness of breath at rest or during exertion and/or fatigue, have symptoms of fluid retention, such as stasis in the pulmonary circulation or oedema around ankles, and the objective data suggest irregularities in the heart structure and functions at rest. The incidence of HF in Europe varies from 2 to 3%, but it increases rapidly around the age of 75 (10-20% in the age group of 70-80 years). Coronary artery disease is still the most frequent cause of myocardial disease and it is estimated to be a causative factor in about 70% of HF patients. The general prognosis in HF is poor; on average 50% of HF patients die within 4 years of the diagnosis [69] .
The adrenergic nervous system plays one of the major roles in HF pathophysiology. The primary changes in HF are characte- Review rised by the increased activity of the adrenergic system (however, the precise cause of sympathetic activation in HF is not known).
Initially, the increased sympathetic activation (greater conductivity in the sympathetic nerves) is a compensating mechanism:
increased noradrenaline (NE) secretion from the neuron terminal of the myocardial adrenergic system causes a greater amount of NE in the synaptic cleft and increases the myocardial contractility and heart rate. A small fraction of NE passes from the cleft to the blood circulation and thus increases the NE level in blood plasma, and the remaining NE is transported by NET back to the nerve terminal; increased NE secretion is usually associated with reduced NE reuptake to the nerve terminal due to the reduced sensitivity of the NET transporter. In patients with chronic HF the greater activity of the myocardial adrenergic system has adverse effects -increased NE concentration in the synaptic cleft decreases the sensitivity of post-synaptic adrenergic beta-1 receptors on the cardiomyocyte membrane, reduces the activation conductivity and contributes to the impairment of heart functions.
These changes in the activity of the myocardial adrenergic system are also relevant to the generation of ventricular arrhythmias and sudden cardiac death in HF patients.
As the reduced NE reuptake contributes to the low MIBG concentration in neurons (reduced H/M ratio) and the increased NE secretion causes greater MIBG washout (greater WR value),
an assessment of the activity of the adrenergic system based on MIBG as well as H/M and WR imaging parameters is used for obtaining prognostic information in the case of HF patients.
The study of Merlet et al., published in 1992, was the first report
showing that the myocardial MIBG uptake is a strong predictive factor for cardiac events in the case of patients with chronic HF [31] . Low H/M value was determined to be the best independent predictor of the death rate, better than low EF value: after 20 months the survival rate was 10% in the case of patients with H/M < 1.22, and 30% in the case of patients with EF < 20%.
It has been shown in a number of single-centre studies that the myocardial MIBG uptake has a prognostic value for HF pa- The main cause of death in the case of HF patients is cardiac death due to ventricular disorders of heart rate. In the case of some patients the final arrhythmia is a natural result of the end-stage irreversible heart pump dysfunction; while in the case of some patients functioning quite well, sudden cardiac death (SCD) occurs. It was suggested in numerous studies that the disorders of MIBG uptake can be used as predictors of the higher risk of serious ventricular arrhythmias and SCD [43, [70] [71] [72] [73] The reduced MIBG uptake and the corresponding degeneration of the myocardial sympathetic innervation was observed in early stages of DLB and PD by Suzuki et al., and the functions of the adrenergic system, measured with the H/M ratio, was significantly reduced in DLB patients compared to PD patients [81] .
In the differentiation between DLB and Alzheimer's disease it was shown that the H/M ratio is significantly lower in DLB patients [82, 83] . In the studies of Yoshita et al. the optimised threshold value at 1.68 for H/M 4h enabled 100% sensitivity and specificity of the differentiation process; it was also shown that the WR value at 23.6% enables differentiating between DLB (with greater washout rate) and Alzheimer's disease with sensitivity at 84% and specificity at 83% [83] . However, the sensitivity of MIBG-based myocardial scintigraphy in detecting early stage of Parkinson's disease seems to be limited.
